Neuren Pharmaceuticals (NEU AU): Ready to Fly Again After a Breather
Neuren shares dip due to disappointing U.S. performance of Daybue. Muted US performance of Daybue in 1H24 seems to be short-lived and the drug is...
372 Views
Neuren Pharmaceuticals (NEU AU): Positive Trial Result- A Step Ahead for Potential Second Drug
Neuren announced positive phase 2 trial results for NNZ-2591 in Phelan-McDermid syndrome, a genetic disorder. NNZ-2591 has the potential to become...
408 Views
2023 in Rear Mirror View: Top Performers From My Global Healthcare Coverage Universe
Despite ongoing recovery and fading effect of the COVID-19, healthcare companies had varying performances in 2023. From my coverage, the top...
603 Views
APAC Healthcare Weekly (Oct 20)- Eisai, Daiichi Sankyo, Junshi Bioscience, Akeso, Celltrion, Neuren
This insight collates key news in APAC healthcare last week. With the earnings season beginning to unfold along with major pharma and healthcare...
328 Views
Clinuvel Pharmaceuticals (CUV AU): Positive Clinical Trial Result; Base Business Going Strong
Clinuvel Pharmaceuticals reported positive results from CUV151 study on DNA-repair capacity of afamelanotide. Expanding patient reach of Scenesse...
410 Views